505-95-3Relevant articles and documents
Pellynols M?O, cytotoxic polyacetylenic alcohols from a Niphates sp. marine sponge
Wang, Jie,Liu, Li-Yun,Liu, Lei,Zhan, Kai-Xuan,Jiao, Wei-Hua,Lin, Hou-Wen
, p. 3701 - 3706 (2018)
Three new polyacetylenic alcohols, pellynols M?O (1–3), along with two known ones, melyne A (4) and melyne B (5), were isolated from a Niphates sp. marine sponge collected off the South China Sea. The structures of new compounds were determined based on a combination of 1D and 2D NMR analysis, ESI-MSn fragmentation, and chemical (ozonolysis) method. Their absolute configurations were assigned by modified Mosher's method. All the isolates showed potent cytotoxic activity against PC9 and HepG2 human cancer cell lines with IC50 values of 2.9–7.6 μM.
Liglaurates A–E, cytotoxic bis(lauric acid-12yl)lignanoates from the rhizomes of Drynaria roosii Nakaike
He, Wenwen,Wang, Dongyang,Wang, Liping,Wu, Dan,Wufuer, Halidan,Xu, Yanchao,Zhu, Weiming
, (2022/03/09)
Five undescribed bis(lauric acid-12-yl)lignanoates, liglaurates A–E, along with the known methyl and glyceryl 12-caffeoyloxylaurates were isolated from the rhizomes of Drynaria roosii Nakaike. Their structures including absolute configurations were determined by HRESIMS, NMR techniques, and ECD calculation. Liglaurates A–D were isolated as the racemates, among which (±)-liglaurate A and (±)-liglaurate B were synthesized by a metal-mediated oxidative coupling reaction and further resolved as the enantiomerically pure compounds. Liglaurates (+)-A, (?)-A, (+)-B, (?)-B, (±)-C and (±)-D exhibited remarkable cytotoxic activities against HeLa cell line, with the IC50 values of 0.11 ± 0.02, 0.24 ± 0.01, 0.02 ± 0.00, 0.13 ± 0.02, 0.34 ± 0.07 and 0.17 ± 0.01 μM, respectively.
Novel insights into oxidation of fatty acids and fatty alcohols by cytochrome P450 monooxygenase CYP4B1
Thesseling, Florian A.,Hutter, Michael C.,Wiek, Constanze,Kowalski, John P.,Rettie, Allan E.,Girhard, Marco
, (2019/12/12)
CYP4B1 is an enigmatic mammalian cytochrome P450 monooxygenase acting at the interface between xenobiotic and endobiotic metabolism. A prominent CYP4B1 substrate is the furan pro-toxin 4-ipomeanol (IPO). Our recent investigation on metabolism of IPO related compounds that maintain the furan functionality of IPO while replacing its alcohol group with alkyl chains of varying structure and length revealed that, in addition to cytotoxic reactive metabolite formation (resulting from furan activation) non-cytotoxic ω-hydroxylation at the alkyl chain can also occur. We hypothesized that substrate reorientations may happen in the active site of CYP4B1. These findings prompted us to re-investigate oxidation of unsaturated fatty acids and fatty alcohols with C9–C16 carbon chain length by CYP4B1. Strikingly, we found that besides the previously reported ω- and ω-1-hydroxylations, CYP4B1 is also capable of α-, β-, γ-, and δ-fatty acid hydroxylation. In contrast, fatty alcohols of the same chain length are exclusively hydroxylated at ω, ω-1, and ω-2 positions. Docking results for the corresponding CYP4B1-substrate complexes revealed that fatty acids can adopt U-shaped bonding conformations, such that carbon atoms in both arms may approach the heme-iron. Quantum chemical estimates of activation energies of the hydrogen radical abstraction by the reactive compound 1 as well as electron densities of the substrate orbitals led to the conclusion that fatty acid and fatty alcohol oxidations by CYP4B1 are kinetically controlled reactions.
Heme-thiolate sulfenylation of human cytochrome P450 4A11 functions as a redox switch for catalytic inhibition
Albertolle, Matthew E.,Kim, Donghak,Nagy, Leslie D.,Yun, Chul-Ho,Pozzi, Ambra,Savas, üzen,Johnson, Eric F.,Guengerich, F. Peter
, p. 11230 - 11242 (2017/08/08)
Cytochrome P450 (P450, CYP) 4A11 is a human fatty acid ω-hydroxylase that catalyzes the oxidation of arachidonic acid to the eicosanoid 20-hydroxyeicosatetraenoic acid (20-HETE), which plays important roles in regulating blood pressure regulation. Variants of P450 4A11 have been associated with high blood pressure and resistance to anti-hypertensive drugs, and 20-HETE has both pro- and antihypertensive properties relating to increased vasoconstriction and natriuresis, respectively. These physiological activities are likely influenced by the redox environment, but the mechanisms are unclear. Here, we found that reducing agents (e.g. dithiothreitol and tris(2-carboxyethyl) phosphine) strongly enhanced the catalytic activity of P450 4A11, but not of 10 other human P450s tested. Conversely, added H2O2 attenuated P450 4A11 catalytic activity. Catalytic roles of five of the potentially eight implicated Cys residues of P450 4A11 were eliminated by site-directed mutagenesis. Using an isotope-coded dimedone/iododimedone-labeling strategy and mass spectrometry of peptides, we demonstrated that the heme-thiolate cysteine (Cys-457) is selectively sulfenylated in an H2O2 concentration-dependent manner. This sulfenylation could be reversed by reducing agents, including dithiothreitol and dithionite. Of note, we observed heme ligand cysteine sulfenylation of P450 4A11 ex vivo in kidneys and livers derived from CYP4A11 transgenic mice. We also detected sulfenylation of murine P450 4a12 and 4b1 heme peptides in kidneys. To our knowledge, reversible oxidation of the heme thiolate has not previously been observed in P450s and may have relevance for 20-HETE-mediated functions.
Tandem Reductive Hydroformylation of Castor Oil Derived Substrates and Catalyst Recycling by Selective Product Crystallization
Furst, Marc R. L.,Korkmaz, Vedat,Gaide, Tom,Seidensticker, Thomas,Behr, Arno,Vorholt, Andreas J.
, p. 4319 - 4323 (2017/12/15)
An orthogonal tandem catalytic system consisting of rhodium and ruthenium complexes yielded linear C12 α,ω-bifunctional compounds from commercial, castor oil derived renewable substrates. With aldehyde yields up to 88 % and selectivities to the linear species of up to 95 %, this approach is direct and atom economic and provides easy access to potential polymer precursors for polycondensates. Additionally, a straightforward method for selective product crystallization was developed, which enabled recycling of the tandem catalytic system for two runs with excellent activity and simultaneously provided a high-purity product.
Whole-cell microtiter plate screening assay for terminal hydroxylation of fatty acids by P450s
Weissenborn, Martin J.,Notonier, Sandra,Lang, Sarah-Luise,Otte, Konrad B.,Herter, Susanne,Turner, Nicholas J.,Flitsch, Sabine L.,Hauer, Bernhard
supporting information, p. 6158 - 6161 (2016/05/19)
A readily available galactose oxidase (GOase) variant was used to develop a whole cell screening assay. This endpoint detection system was applied in a proof-of-concept approach by screening a focussed mutant library. This led to the discovery of the thus far most active P450 Marinobacter aquaeolei mutant catalysing the terminal hydroxylation of fatty acids.
ALKANE OXIDATION BY MODIFIED HYDROXYLASES
-
Paragraph 0339, (2016/02/16)
This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells.
From Alkanes to Carboxylic Acids: Terminal Oxygenation by a Fungal Peroxygenase
Olmedo, Andrés,Aranda, Carmen,del Río, José C.,Kiebist, Jan,Scheibner, Katrin,Martínez, Angel T.,Gutiérrez, Ana
supporting information, p. 12248 - 12251 (2016/10/13)
A new heme–thiolate peroxidase catalyzes the hydroxylation of n-alkanes at the terminal position—a challenging reaction in organic chemistry—with H2O2as the only cosubstrate. Besides the primary product, 1-dodecanol, the conversion of dodecane yielded dodecanoic, 12-hydroxydodecanoic, and 1,12-dodecanedioic acids, as identified by GC–MS. Dodecanal could be detected only in trace amounts, and 1,12-dodecanediol was not observed, thus suggesting that dodecanoic acid is the branch point between mono- and diterminal hydroxylation. Simultaneously, oxygenation was observed at other hydrocarbon chain positions (preferentially C2 and C11). Similar results were observed in reactions of tetradecane. The pattern of products formed, together with data on the incorporation of18O from the cosubstrate H218O2, demonstrate that the enzyme acts as a peroxygenase that is able to catalyze a cascade of mono- and diterminal oxidation reactions of long-chain n-alkanes to give carboxylic acids.
DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR
-
, (2015/04/15)
The present invention provides a novel dihydroorotic acid dehydrogenase inhibitor which is applicable to various diseases. When used as an active ingredient, a compound represented by formula (I): (wherein X represents a halogen atom, R1 represents a hydrogen atom, R2 represents an alkyl group containing 1 to 7 carbon atoms, R3 represents -CHO, and R4 represents -CH2-CH=C(CH3)-R0 (wherein R0 represents an alkyl group containing 1 to 12 carbon atoms which may have a substituent on the terminal carbon and/or on a non-terminal carbon, etc.)), an optical isomer thereof or a pharmaceutically acceptable salt thereof has a high inhibitory effect on dihydroorotic acid dehydrogenase and can be used as an immunosuppressive agent, a therapeutic agent for rheumatism, an anticancer agent, a therapeutic agent for graft rejection, an antiviral agent, an anti-H. pylori agent, a therapeutic agent for diabetes or the like.
NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT
-
, (2013/09/26)
Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I) (wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents -CHO, -C(=O)R5, -COOR5 (wherein R5 represents a C1-7 alkyl group), -CH2OH or -COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and/or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.
